Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 19/20 | 0.52 |
| ▸ | HTR3E | A5X5Y0 | 6/20 | 0.52 |
| ▸ | HTR3B | O95264 | 6/20 | 0.52 |
| ▸ | HTR3A | P46098 | 6/20 | 0.52 |
| ▸ | HTR3D | Q70Z44 | 6/20 | 0.52 |
| ▸ | HTR3C | Q8WXA8 | 6/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5653612 | 0.93 | CHRNA7 (0.52) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7064078 | 0.79 | CHRNA7 (0.74) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7114094 | 0.79 | CHRNA7 (0.74) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7063810 | 0.79 | CHRNA7 (0.77) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL11920205 | 0.75 | CHRNA7 (0.75) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL2892986 | 0.74 | CHRNA7 (0.74) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL21017869 | 0.74 | CHRNA7 (0.56) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7064246 | 0.73 | CHRNA7 (0.74) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5651073 | 0.72 | MEN1 (0.51) | — | |
| SCHEMBL7127110 | 0.72 | HDAC3 (0.64) | CHRNA7HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | 3-V BIOSCIENCES, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | NR0B2, NR0B1, NCOR1 | CHRNA7 3434/4885HTR3E 3894/4885HTR3B 2281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.